Trial Profile
Phase II Trial of Temozolomide and Caelyx in the Treatment of Patients with Glioblastoma Multiforme following concurrent radiotherapy and chemotherapy to improve six month progression free survival
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Jun 2016
Price :
$35
*
At a glance
- Drugs Doxorubicin liposomal (Primary) ; Temozolomide (Primary) ; Antineoplastics
- Indications Glioblastoma
- Focus Therapeutic Use
- Sponsors Schering-Plough
- 08 Jun 2016 Status changed from not yet recruiting to completed.
- 30 Aug 2011 New trial record